SG3 Management’s BeOne Medicines Ltd ONC Stock Holding History

SG3 Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$943K	–	910
2022 Q1	$943K	Sell	5,000 -10,000	-67%	-$2.13M	0.03%	472
2021 Q4	$4.06M	Hold	15,000	–	–	0.08%	215
2021 Q3	$5.45M	Buy	+15,000	New	+$4.9M	0.17%	129
2021 Q2	–	Sell	-23,500	Closed	-$8.18M	–	1403
2021 Q1	$8.18M	Buy	23,500 +10,000	+74%	+$3.31M	0.2%	111
2020 Q4	$3.49M	Buy	13,500 +8,500	+170%	+$2.34M	0.07%	264
2020 Q3	$1.43M	Buy	+5,000	New	+$1.18M	0.05%	345
2020 Q1	–	Sell	-6,500	Closed	-$1.08M	–	472
2019 Q4	$1.08M	Sell	6,500 -1,600	-20%	-$266K	0.07%	96
2019 Q3	$992K	Buy	+8,100	New	+$1.08M	0.09%	134

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

SG3 Management's ONC Position: Q1 2022 in Review

SG3 Management sold out of BeOne Medicines Ltd (ONC) in Q1 2022, closing a stake of 2,500 shares — an estimated $531K sold.

SG3 Management first reported a position in ONC in Q3 2021 and held it in 2 quarters. The position peaked at $1.45M in Q3 2021. 238 funds tracked by Wall St. Rank hold ONC as of Q1 2022.

SG3 Management reported no remaining BeOne Medicines Ltd position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 2,500 BeOne Medicines Ltd shares in Q1 2022, an estimated $531K.
SG3 Management first reported a position in BeOne Medicines Ltd in Q3 2021 and held it in 2 quarters.
SG3 Management's BeOne Medicines Ltd position peaked at $1.45M in Q3 2021.
238 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.